Bennett Gavin, Joyce Mary, Sweeney Louise, MacLoughlin Ronan
Aerogen Limited, IDA Business Park, Dangan, Galway, Ireland.
Pulm Ther. 2018 Jun;4(1):73-86. doi: 10.1007/s41030-018-0054-x. Epub 2018 Apr 18.
The use of concurrent aerosol delivery during high-flow nasal therapy (HFNT) may be exploited to facilitate the delivery of a variety of prescribed medications for inhalation. Until now, a systematic approach to determine the conditions required to yield an optimal emitted dose has not been reported. The aim of this study was to establish the effects of gas flow rate, input droplet size, and nebulizer position on the amount of aerosol exiting the nasal cannula during HFNT and thus becoming available for inhalation.
Testing was completed according to a factorial statistical design of experiments (DOE) approach. Emitted dose was characterized with a vibrating mesh nebulizer (Aerogen Solo, Aerogen Ltd) for an adult model of HFNT at three clinically relevant gas flow rates, using three nebulizers producing varying input droplet sizes and placed at two different nebulizer positions.
Increasing the gas flow rate significantly lowered the emitted dose, with a dose of 7.10% obtained at 10 LPM, 2.67% at 25 LPM, and 1.30% at 40 LPM (p < 0.0001). There was a significant difference in emitted dose between nebulizers with different input droplet sizes, with increasing input droplet size associated with a reduced emitted dose (6.11% with an input droplet size of 3.22 µm, 2.76% with 4.05 µm, and 2.38% with 4.88 µm, p = 0.0002, Pearson's r = - 0.2871). In addition, the droplet size exiting the nasal cannula interface was lower than that produced by the aerosol generator for all devices under test. Positioning the nebulizer immediately after the humidification chamber yielded a marginally greater emitted dose (3.79%) than when the nebulizer was placed immediately upstream of the nasal cannula (3.39%). Flow rate, input droplet size, and nebulizer position were at the 0.10 level of significance, indicating that all three factors had significant effects on emitted dose. According to the DOE model, flow rate had the greatest influence on emitted dose, followed by input droplet size and then nebulizer position.
Our findings indicate that in order to optimize the amount of aerosol exiting the nasal cannula interface during HFNT, it is necessary for gas flow rate to be low and the input droplet size to be small, while the nebulizer should be positioned immediately after the humidification chamber.
Aerogen Limited.
在高流量鼻导管治疗(HFNT)期间使用同步气溶胶输送,可用于促进各种吸入用处方药的输送。到目前为止,尚未有系统的方法来确定产生最佳喷出剂量所需的条件。本研究的目的是确定气体流速、输入液滴大小和雾化器位置对HFNT期间从鼻导管出来并可供吸入的气溶胶量的影响。
根据析因统计实验设计(DOE)方法完成测试。使用振动网式雾化器(Aerogen Solo,Aerogen有限公司),针对成人HFNT模型,在三种临床相关气体流速下,使用三种产生不同输入液滴大小的雾化器,并将其放置在两个不同的雾化器位置,对喷出剂量进行表征。
提高气体流速显著降低了喷出剂量,在10升/分钟时剂量为7.10%,25升/分钟时为2.67%,40升/分钟时为1.30%(p<0.0001)。不同输入液滴大小的雾化器之间喷出剂量存在显著差异,输入液滴大小增加与喷出剂量降低相关(输入液滴大小为3.22微米时为6.11%,4.05微米时为2.76%,4.88微米时为2.38%,p = 0.0002,Pearson相关系数r = - 0.2871)。此外,对于所有测试设备,从鼻导管接口出来的液滴大小低于气溶胶发生器产生的液滴大小。将雾化器放置在加湿室之后,喷出剂量(3.79%)略高于将雾化器放置在鼻导管紧上游时(3.39%)。流速、输入液滴大小和雾化器位置在0.10显著性水平上,表明这三个因素对喷出剂量均有显著影响。根据DOE模型,流速对喷出剂量影响最大,其次是输入液滴大小,然后是雾化器位置。
我们的研究结果表明,为了优化HFNT期间从鼻导管接口出来的气溶胶量,气体流速需要较低,输入液滴大小需要较小,同时雾化器应放置在加湿室之后。
Aerogen有限公司。